Kalyan Roy: A New Era in Thalassemia Treatment – FDA Approves Mitapivat
Kalyan Roy, Specialist Transfusion Medicine Center at Square Hospitals LTD, shared a post on LinkedIn:
“A New Era in Thalassemia Treatment: FDA Approves Mitapivat (Aqvesme)
A significant milestone in hematology! The US FDA has approved Mitapivat (Aqvesme), the first oral treatment for anemia in adults with alpha- and beta-thalassemia.
Why is this important?
Mitapivat is an oral pyruvate kinase activator that improves red blood cell energy metabolism by increasing ATP production, potentially enhancing RBC function and survival.
Key Clinical Trial Findings:
ENERGIZE-T (Transfusion-Dependent Thalassemia):
- 30% of patients receiving mitapivat achieved a transfusion reduction response, compared with 13% receiving placebo.
ENERGIZE (Non-Transfusion-Dependent Thalassemia):
- 42% achieved a hemoglobin response, compared with only 2% in the placebo group.
Clinical Significance:
A new oral therapeutic option for adult thalassemia patients.
Potential reduction in transfusion burden.
Improvement in hemoglobin levels and patient-reported fatigue.
A novel approach targeting RBC metabolism rather than correcting the underlying genetic defect.
Important Safety Note: Liver toxicity is a significant concern.
Treatment requires appropriate monitoring and compliance with the FDA’s restricted REMS program.
The Take-Home Message:
Mitapivat is not a cure for thalassemia, nor does it eliminate transfusion requirements for every patient.
However, it represents an exciting advance in metabolic-targeted therapy and offers new hope for improving the management of inherited red blood cell disorders.
A promising step towards more personalized and less transfusion-dependent thalassemia care!
Reference: US FDA – Approval of Aqvesme (Mitapivat)”
Other posts featuring Kalyan Roy on Hemostasis Today.
-
Nov 14, 2026, 11:24Can Iron Deficiency Really be Seen in Someone’s Face? – ASH
-
Nov 14, 2026, 11:19Lindsay Davison: Putting Childhood Anemia in the Spotlight with IronUp and Danone
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today